Skip to main content

All Wales advice on oral anticoagulation for non-valvular atrial fibrillation

This guidance is an update to the previously available 'All Wales Advice on the Role of Oral Anticoagulants'. It focuses on treatment of patients with non-valvular atrial fibrillation (NVAF) and incorporates an updated version of the AWMSG-endorsed ‘Risk/Benefit Assessment Tool for Oral Anticoagulant Treatment in People with Atrial Fibrillation’, and includes recommendations from ‘Warfarin Monitoring’ (published in June 2012) relevant to the treatment of NVAF.

⇩ All Wales Advice on Oral Anticoagulation for Non-valvular Atrial Fibrillation 1,320KB (PDF)

(March 2020)